Bamco Inc. NY Purchases 1,066,371 Shares of Heartflow, Inc. $HTFL

Bamco Inc. NY boosted its position in Heartflow, Inc. (NASDAQ:HTFL) by 86.2% during the fourth quarter, HoldingsChannel reports. The fund owned 2,303,877 shares of the company’s stock after buying an additional 1,066,371 shares during the quarter. Bamco Inc. NY’s holdings in Heartflow were worth $67,158,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HTFL. JPMorgan Chase & Co. bought a new stake in Heartflow in the 3rd quarter valued at about $13,887,000. Vanguard Group Inc. bought a new stake in Heartflow in the 3rd quarter valued at about $48,871,000. TD Asset Management Inc bought a new stake in Heartflow in the 3rd quarter valued at about $2,692,000. Artisan Partners Limited Partnership bought a new stake in Heartflow in the 3rd quarter valued at about $16,817,000. Finally, Legato Capital Management LLC bought a new stake in Heartflow in the 3rd quarter valued at about $243,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HTFL. William Blair began coverage on Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating on the stock. Wells Fargo & Company upped their price target on Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. JPMorgan Chase & Co. decreased their price target on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Piper Sandler reiterated an “overweight” rating on shares of Heartflow in a research report on Thursday, June 11th. Finally, Canaccord Genuity Group decreased their price target on Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Heartflow Trading Up 2.5%

Shares of NASDAQ HTFL opened at $32.84 on Thursday. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22. The firm has a market capitalization of $2.83 billion and a price-to-earnings ratio of -10.56. The business has a 50-day moving average of $29.74 and a 200-day moving average of $28.34.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.08. The business had revenue of $52.59 million for the quarter. The firm’s revenue for the quarter was up 41.3% on a year-over-year basis. On average, analysts predict that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Insider Transactions at Heartflow

In other news, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $29.23, for a total transaction of $27,732,167.11. Following the completion of the transaction, the insider owned 8,448,158 shares of the company’s stock, valued at approximately $246,939,658.34. The trade was a 10.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Campbell Rogers sold 64,533 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $24.64, for a total value of $1,590,093.12. Following the transaction, the insider directly owned 81,002 shares of the company’s stock, valued at $1,995,889.28. The trade was a 44.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,141,438 shares of company stock valued at $62,651,098. 7.70% of the stock is owned by corporate insiders.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.